Free Trial

OMNI 360 Wealth Inc. Takes $367,000 Position in CME Group Inc. (NASDAQ:CME)

CME Group logo with Finance background

OMNI 360 Wealth Inc. bought a new stake in CME Group Inc. (NASDAQ:CME - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,382 shares of the financial services provider's stock, valued at approximately $367,000.

A number of other hedge funds and other institutional investors have also modified their holdings of CME. Wayfinding Financial LLC acquired a new position in CME Group during the first quarter worth approximately $25,000. New Age Alpha Advisors LLC increased its position in CME Group by 50.0% during the fourth quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock worth $30,000 after buying an additional 43 shares during the last quarter. Golden State Wealth Management LLC increased its position in CME Group by 612.5% during the first quarter. Golden State Wealth Management LLC now owns 114 shares of the financial services provider's stock worth $30,000 after buying an additional 98 shares during the last quarter. Alpine Bank Wealth Management acquired a new position in CME Group during the first quarter worth approximately $32,000. Finally, Knuff & Co LLC acquired a new position in CME Group during the fourth quarter worth approximately $33,000. Institutional investors and hedge funds own 87.75% of the company's stock.

Insider Activity

In other CME Group news, Director Daniel G. Kaye sold 500 shares of the company's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $282.42, for a total transaction of $141,210.00. Following the completion of the sale, the director directly owned 3,668 shares in the company, valued at $1,035,916.56. This represents a 12.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Charles P. Carey sold 500 shares of the company's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $265.35, for a total value of $132,675.00. Following the sale, the director owned 4,900 shares of the company's stock, valued at $1,300,215. The trade was a 9.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,400 shares of company stock valued at $3,680,610. Corporate insiders own 0.30% of the company's stock.

Analyst Ratings Changes

CME has been the topic of a number of recent analyst reports. Citigroup boosted their price target on CME Group from $265.00 to $275.00 and gave the stock a "neutral" rating in a research report on Thursday, July 3rd. Bank of America boosted their price target on CME Group from $200.00 to $219.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 2nd. JPMorgan Chase & Co. lowered their price target on CME Group from $223.00 to $211.00 and set an "underweight" rating on the stock in a research report on Thursday, April 24th. Piper Sandler upped their target price on CME Group from $275.00 to $283.00 and gave the company an "overweight" rating in a research report on Tuesday, April 8th. Finally, UBS Group upped their target price on CME Group from $290.00 to $305.00 and gave the company a "buy" rating in a research report on Friday, April 25th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, CME Group has a consensus rating of "Hold" and a consensus price target of $259.87.

View Our Latest Stock Report on CME

CME Group Price Performance

Shares of CME stock traded down $0.93 during trading on Wednesday, hitting $274.70. The company had a trading volume of 795,504 shares, compared to its average volume of 2,188,462. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.02 and a current ratio of 1.02. The firm has a market capitalization of $98.99 billion, a P/E ratio of 27.65, a price-to-earnings-growth ratio of 3.83 and a beta of 0.44. The stock's 50-day moving average price is $276.76 and its 200 day moving average price is $258.61. CME Group Inc. has a one year low of $193.17 and a one year high of $290.79.

CME Group (NASDAQ:CME - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.61 by $0.19. CME Group had a return on equity of 14.03% and a net margin of 57.71%. The business had revenue of $1.64 billion during the quarter, compared to analysts' expectations of $1.56 billion. During the same period in the previous year, the company posted $2.50 earnings per share. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. Equities analysts expect that CME Group Inc. will post 10.49 EPS for the current fiscal year.

CME Group Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 25th. Shareholders of record on Monday, June 9th were paid a dividend of $1.25 per share. This represents a $5.00 annualized dividend and a yield of 1.82%. The ex-dividend date was Monday, June 9th. CME Group's payout ratio is presently 50.30%.

CME Group Profile

(Free Report)

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

See Also

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Should You Invest $1,000 in CME Group Right Now?

Before you consider CME Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.

While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines